123 related articles for article (PubMed ID: 29587577)
1. Effect of Carbapenem Selection on Drug Acquisition Costs and Carbapenem Resistance.
Smoke SM; Abdul W; Grigoriu A; Vasant D
J Pharm Pract; 2019 Feb; 32(1):7-8. PubMed ID: 29587577
[No Abstract] [Full Text] [Related]
2. A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa.
Hirayama S; Yasui K; Murakami H; Kosugi T; Sakamoto M; Hanai Y; Matsuo K; Miyazaki T; Ishii Y; Nishizawa K; Tateda K
J Infect Chemother; 2018 Dec; 24(12):949-953. PubMed ID: 30268412
[TBL] [Abstract][Full Text] [Related]
3. Carbapenem stewardship: positive impact on hospital ecology.
Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Almeida JN; Félix Cda S; Rossi F
Braz J Infect Dis; 2011; 15(1):1-5. PubMed ID: 21412581
[TBL] [Abstract][Full Text] [Related]
4. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
5. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
[TBL] [Abstract][Full Text] [Related]
6. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Eagye KJ; Nicolau DP
Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.
Sader HS; Castanheira M; Duncan LR; Flamm RK
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):69-74. PubMed ID: 29789189
[TBL] [Abstract][Full Text] [Related]
8. Direct determination of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa from positive blood cultures using laser scattering technology.
Idelevich EA; Hoy M; Knaack D; Görlich D; Peters G; Borowski M; Becker K
Int J Antimicrob Agents; 2018 Feb; 51(2):221-226. PubMed ID: 29111432
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of carbapenem use in a tertiary hospital: antimicrobial stewardship urgently needed.
Zhang D; Cui K; Lu W; Bai H; Zhai Y; Hu S; Li H; Dong H; Feng W; Dong Y
Antimicrob Resist Infect Control; 2019; 8():5. PubMed ID: 30627429
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
11. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
13. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
Eagye KJ; Nicolau DP
J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
[TBL] [Abstract][Full Text] [Related]
14. Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
Ho CM; Ho MW; Liu YC; Toh HS; Lee YL; Liu YM; Huang CC; Lu PL; Liu CE; Chen YH; Ko WC; Tang HJ; Yu KW; Chen YS; Chuang YC; Wang JH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S24-8. PubMed ID: 22749055
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009.
Zilberberg MD; Shorr AF
J Hosp Med; 2013 Oct; 8(10):559-63. PubMed ID: 24022878
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
